SVB Securities analyst David Risinger raised the firm’s price target on Eli Lilly to $458 from $410 and keeps an Outperform rating on the shares. The firm’s investment thesis is that shares can continue to outperform, driven by the company’s market leadership in diabetes/obesity and ability to drive long-term growth above expectations.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on LLY:
- Eli Lilly announces secondary analysis from lebrikizumab study
- Eli Lilly price target raised to $420 from $400 at Barclays
- Eli Lilly price target raised to $430 from $421 at Truist
- Eli Lilly price target raised to $485 from $432 at Cantor Fitzgerald
- Eli Lilly price target raised to $420 from $400 at Credit Suisse
